| Identification | Back Directory | [Name]
5H-Dibenzo[a,d]cycloheptene-2,8-dicarboxamide, 5-[(2S)-2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]propyl]-10,11-dihydro-N2,N2,N8,N8-tetramethyl-5-(2H-tetrazol-5-yl)- | [CAS]
913978-37-7 | [Synonyms]
AMG222
AMG-222
AMG 222
ALS-20426
ALS-2-0426
ALS-2-0426 free base
5H-Dibenzo[a,d]cycloheptene-2,8-dicarboxamide, 5-[(2S)-2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]propyl]-10,11-dihydro-N2,N2,N8,N8-tetramethyl-5-(2H-tetrazol-5-yl)- | [Molecular Formula]
C32H39N9O3 | [MOL File]
913978-37-7.mol | [Molecular Weight]
597.71 |
| Hazard Information | Back Directory | [Uses]
AMG-222 is a dipeptidyl peptidase IV (DPP-IV) inhibitor that exerts its inhibitory effect by tightly and reversibly binding to DPPIV. AMG 222 binds to human plasma proteins in a saturable and concentration-dependent manner, with a binding rate of 80.8% at 1 nM, while the binding rate decreases to 29.4% at concentrations above 100 nM. AMG-222 can be used in research related to diabetes[1]. | [IC 50]
DPP-4 | [References]
[1] Greene R J, et al. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222[J]. Xenobiotica, 2011, 41(11): 945-957. DOI:10.3109/00498254.2011.597455 |
|
|